Grants and Contributions:
Title:
Plasmid Design Optimization to Enhance Immunogenicity of Salmonella-based Vaccines for Cellular and Antibody Immune Responses
Agreement Number:
957439
Agreement Value:
$46,794.00
Agreement Date:
Oct 1, 2020 - Mar 31, 2021
Description:
The project seeks to develop novel plasmid constructs that enhance the expression and presentation of exogenous antigens upon delivery to a mammal via Salmonella vaccine vector. The vaccines will be developed for use in infectious disease and cancer indications.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Halifax, Nova Scotia, CA B3N 3J2
Reference Number:
172-2020-2021-Q3-957439
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
709813281
Recipient Type:
For-profit organization
Recipient's Operating Name:
Avanda Biolabs
Recipient's Legal Name:
Avanda Biolabs Limited
Federal Riding Name:
Halifax
Federal Riding Number:
12005
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410